Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Georg Heinrich

Showing results (11-20 of 21) with videos related to

Pageof 3
Sort By:
Intensive Care Medicine|January 21, 2015
The association between ICU level of care and mortality in the NetherlandsGeorg Heinrich Kluge, Sylvia Brinkman, Giel van Berkel, et al.
Cancers|August 26, 2022
Does the Presence of Circulating Tumor Cells in High-Risk Early Breast Cancer Patients Predict the Site of First Metastasis-Results from the Adjuvant SUCCESS A TrialElisabeth K Trapp, Peter A Fasching, Tanja Fehm, et al.
International Journal of Cancer|April 29, 2026
Chemotherapy-Induced Nausea and Vomiting in Early Breast Cancer Patients Receiving Adjuvant Chemotherapy With Fluorouracil, Epirubicin, Cyclophosphamide Followed by Docetaxel Versus an Anthracycline-Free Regimen With Docetaxel, Cyclophosphamide-Results From a Randomized Clinical TrialManuel Hörner, Henning Schäffler, Lothar Häberle, et al.
Gynecologic Oncology Research and Practice|March 14, 2017
Preference of elderly patients' to oral or intravenous chemotherapy in heavily pre-treated recurrent ovarian cancer: final results of a prospective multicenter trialRadoslav Chekerov, Philipp Harter, Stefan Fuxius, et al.
Clinical Breast Cancer|February 14, 2017
Prevalence of Circulating Tumor Cells After Adjuvant Chemotherapy With or Without Anthracyclines in Patients With HER2-negative, Hormone Receptor-positive Early Breast CancerAmelie Schramm, Fabienne Schochter, Thomas W P Friedl, et al.
Geburtshilfe Und Frauenheilkunde|November 9, 2023
The Endocrine Treatment Landscape for Patients with HR+ HER2- Early-stage Breast Cancer in Germany Before the Introduction of CDK4/6 Inhibitor Therapy - A Real-World AnalysisNaiba Nabieva, Falk Altmann, Klaus Apel, et al.
JAMA Oncology|June 24, 2021
Prognosis of Patients With Early Breast Cancer Receiving 5 Years vs 2 Years of Adjuvant Bisphosphonate Treatment: A Phase 3 Randomized Clinical TrialThomas W P Friedl, Tanja Fehm, Volkmar Müller, et al.
Oncotarget|November 5, 2017
Clinical validation of genetic variants associated with <i>in vitro</i> chemotherapy-related lymphoblastoid cell toxicityPeter A Fasching, Lothar Häberle, Brigitte Rack, et al.
Cancers|April 12, 2022
MUC1 (CA27.29) before and after Chemotherapy and Prognosis in High-Risk Early Breast Cancer PatientsHanna Huebner, Lothar Häberle, Volkmar Müller, et al.
Breast Cancer Research : BCR|October 24, 2020
Gemcitabine as adjuvant chemotherapy in patients with high-risk early breast cancer-results from the randomized phase III SUCCESS-A trialAmelie de Gregorio, Lothar Häberle, Peter A Fasching, et al.
Pageof 3

Showing results (11-20 of 21) with videos related to

Sort By:
Pageof 3
Intensive Care Medicine|January 21, 2015
The association between ICU level of care and mortality in the NetherlandsGeorg Heinrich Kluge, Sylvia Brinkman, Giel van Berkel, et al.
Cancers|August 26, 2022
Does the Presence of Circulating Tumor Cells in High-Risk Early Breast Cancer Patients Predict the Site of First Metastasis-Results from the Adjuvant SUCCESS A TrialElisabeth K Trapp, Peter A Fasching, Tanja Fehm, et al.
International Journal of Cancer|April 29, 2026
Chemotherapy-Induced Nausea and Vomiting in Early Breast Cancer Patients Receiving Adjuvant Chemotherapy With Fluorouracil, Epirubicin, Cyclophosphamide Followed by Docetaxel Versus an Anthracycline-Free Regimen With Docetaxel, Cyclophosphamide-Results From a Randomized Clinical TrialManuel Hörner, Henning Schäffler, Lothar Häberle, et al.
Gynecologic Oncology Research and Practice|March 14, 2017
Preference of elderly patients' to oral or intravenous chemotherapy in heavily pre-treated recurrent ovarian cancer: final results of a prospective multicenter trialRadoslav Chekerov, Philipp Harter, Stefan Fuxius, et al.
Clinical Breast Cancer|February 14, 2017
Prevalence of Circulating Tumor Cells After Adjuvant Chemotherapy With or Without Anthracyclines in Patients With HER2-negative, Hormone Receptor-positive Early Breast CancerAmelie Schramm, Fabienne Schochter, Thomas W P Friedl, et al.
Geburtshilfe Und Frauenheilkunde|November 9, 2023
The Endocrine Treatment Landscape for Patients with HR+ HER2- Early-stage Breast Cancer in Germany Before the Introduction of CDK4/6 Inhibitor Therapy - A Real-World AnalysisNaiba Nabieva, Falk Altmann, Klaus Apel, et al.
JAMA Oncology|June 24, 2021
Prognosis of Patients With Early Breast Cancer Receiving 5 Years vs 2 Years of Adjuvant Bisphosphonate Treatment: A Phase 3 Randomized Clinical TrialThomas W P Friedl, Tanja Fehm, Volkmar Müller, et al.
Oncotarget|November 5, 2017
Clinical validation of genetic variants associated with <i>in vitro</i> chemotherapy-related lymphoblastoid cell toxicityPeter A Fasching, Lothar Häberle, Brigitte Rack, et al.
Cancers|April 12, 2022
MUC1 (CA27.29) before and after Chemotherapy and Prognosis in High-Risk Early Breast Cancer PatientsHanna Huebner, Lothar Häberle, Volkmar Müller, et al.
Breast Cancer Research : BCR|October 24, 2020
Gemcitabine as adjuvant chemotherapy in patients with high-risk early breast cancer-results from the randomized phase III SUCCESS-A trialAmelie de Gregorio, Lothar Häberle, Peter A Fasching, et al.
Pageof 3